A Comparative, Multicenter, Placebo-Controlled, Double-Blind Phase II Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Inhaled Aviptadil in Patients 18 Years and Older With COVID-19 Pulmonary Involvement - HOPE
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- Covid19
- Sponsor
- Centurion Pharma
- Enrollment
- 80
- Locations
- 9
- Primary Endpoint
- Clinical improvement
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months. In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method. In the event that patients need intensive care in the study, the patients will be taken into intensive care unit and excluded from the study and their treatment will be continued in the intensive care unit as deemed appropriate by the physician and it is foreseen that inhaled Aviptadil will be used for a period of minimum 7 and maximum 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. This study includes 8 visits, consisting of a total of 7 physical visits and 1 phone follow-up visit. The study period will be 6 months for each patient. Patient recruitment is planned to take 12 months. Study centers will be asked to use investigational products for their patients who sign the informed consent form for 12 months. The study population will consist of patients 18 years of age and older with COVID-19 pulmonary involvement and hospitalized patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1.18 years and older women or men, under 70 years old
- •2.Patients with positive SARS-CoV-2 real time PCR result and an appearance in line with COVID-19 pneumonia on thorax CT
- •Need for oxygen support or SpO2 \<94 in room air
- •Patients who can use a nebulizer (with assistance when necessary)
- •5.Patients who are willing and capable (mentally and physically) who can sign a written informed consent form, to participate in all aspects of the study, to participate in the planned visits and to comply with the terms of the protocol.
Exclusion Criteria
- •Intensive care admission
- •The need for mechanical ventilation
- •Patients with previously known organ (kidney, heart and liver) failure
- •\* To be determined as previously known heart failure (EF \<30), previously known liver failure (Child-Pugh C) and previously known renal failure (Cr.clerance \<30).
- •COVID-19 disease with no indication for hospitalization
- •Participants in another clinical trial
- •Pregnancy or lactation
- •Solid organ or stem cell transplantation story
- •Patients with collagen tissue disease
- •Use of immunosuppressive therapy
Arms & Interventions
Standard Treatment + Placebo
Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
Intervention: Placebo
Standard Treatment + Inhaled Aviptadil
In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
Intervention: Inhaled Aviptadil
Outcomes
Primary Outcomes
Clinical improvement
Time Frame: 6 months
Being discharged within 30 days of starting treatment, no need for oxygen support
Secondary Outcomes
- Normalization in Respiration Rate/Minute(14 days)
- Time to discharge of patients(6 months)
- Change in SpO2 (measured by pulse oximetry)(6 months)
- The time it takes for the PCR to become negative(14 days)
- Sequelae and recovery rates in control thorax computed tomography at the end of month 1 and 6 months(6 months)
- Need for re-hospitalization(6 months)
- The rate of patients entering intensive care(6 months)
- Patients' rate of needing mechanical ventilation(6 months)
- Normalization in body temperature(14 days)
- Normalization in laboratory results of blood parameters (PT, aPTT, D-dimer, Ferritin, Lymphocyte Count, CRP)(28 days)
- Normalization in laboratory results of biochemistry parameters (Glucose, ALT, AST, LDH, Total Bilirubin, Total Protein, Albumin, Alkaline Phosphatase, GGT, Sodium, Potassium, Calcium, Phosphor, CPK, Magnesium, eGFR, BUN, Uric Acid, Creatinine Clearance)(28 days)
- Mortality rate(6 months)
- Normalization in Blood Pressure(14 days)
- Dyspnea Scale (Modified Borg Dyspnea Scale (MBS)(6 months)
- 6-minute walking test(28 days)
- The time it takes for patients to improvement of their symptoms (cough, shortness of breath)(6 months)
- Normalization in SpO2(14 days)